We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Three Reasons to Add PacBio (PACB) Stock to Your Portfolio
Read MoreHide Full Article
Pacific Biosciences of California, Inc. (PACB - Free Report) , popularly known as PacBio, has been gaining from its slew of strategic deals over the past few months. The optimism led by a solid second-quarter 2023 performance and its product development activities are expected to contribute further. However, stiff competition and macroeconomic concerns persist.
Over the past year, this Zacks Rank #2 (Buy) stock has gained 34.5% compared with 0.2% growth of the industry and a 17.5% rise of the S&P 500.
The renowned global provider of sequencing systems has a market capitalization of $2.06 billion. The company projects 14.5% growth for 2023 and expects to maintain a strong performance. PacBio’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and broke even once, the average surprise being 9.5%.
Image Source: Zacks Investment Research
Let’s delve deeper.
Strategic Deals: We are optimistic about PacBio’s robust growth opportunities via its inking of a slew of strategic deals over the past few months. In August, the company and GeneDx announced a research collaboration with the University of Washington to study the capabilities of HiFi long-read whole genome sequencing to increase diagnostic rates in pediatric patients with genetic conditions.
Also, in August, PacBio entered into an agreement to acquire Apton Biosystems, Inc.
Product Development Activities: We are optimistic about PacBio's solid potential in the RNA-sequencing market, which has been fortifying the company’s footprint worldwide. In August, PacBio announced the commencement of customer shipments of Onso short-read sequencing instruments.
In April, PacBio announced the availability of its new high-throughput Nanobind DNA Extraction kits, another key product from its Circulomics acquisition.
Strong Q2 Results: PacBio saw a robust increase in its overall top line, including strong Product and Instrument revenues, in the second quarter of 2023. Solid geographical performances were also recorded. Continued strong prospects in the Revio and Onso systems, with customers placing orders for these, were also seen.
Downsides
Macroeconomic Concerns: Macroeconomic dynamics, including rising inflation and global supply-chain constraints, have adversely impacted PacBio’s customers and lengthened customer sales cycles. These factors could impact its revenues and results of operations throughout 2023.
Stiff Competition: PacBio operates in a highly competitive market where its competitors offer nucleic acid sequencing equipment or consumables. Many of these companies currently have greater resources and may be able to respond more quickly and effectively than PacBio to new or changing opportunities, technologies, standards or customer requirements.
Estimate Trend
PacBio has been witnessing a positive estimate revision trend for 2023. Over the past 90 days, the Zacks Consensus Estimate for its adjusted loss per share has narrowed from $1.29 to $1.18.
The Zacks Consensus Estimate for the company’s third-quarter 2023 revenues is pegged at $48.1 million, suggesting a 48.9% uptick from the year-ago quarter’s reported number.
Other Key Picks
A few other top-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , McKesson Corporation (MCK - Free Report) and Integer Holdings Corporation (ITGR - Free Report) .
DaVita, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 12.7%. DVA’s earnings surpassed estimates in three of the trailing four quarters and missed once, with an average surprise of 21.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DaVita has gained 4.7% against the industry’s 5.2% decline over the past year.
McKesson, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 10.7%. MCK’s earnings surpassed estimates in three of the trailing four quarters and missed once, with an average of 8.1%.
McKesson has gained 28.6% compared with the industry’s 50.9% rise over the past year.
Integer Holdings, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.1%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 8.4%.
Integer Holdings has gained 52.6% compared with the industry’s 0.2% rise over the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Three Reasons to Add PacBio (PACB) Stock to Your Portfolio
Pacific Biosciences of California, Inc. (PACB - Free Report) , popularly known as PacBio, has been gaining from its slew of strategic deals over the past few months. The optimism led by a solid second-quarter 2023 performance and its product development activities are expected to contribute further. However, stiff competition and macroeconomic concerns persist.
Over the past year, this Zacks Rank #2 (Buy) stock has gained 34.5% compared with 0.2% growth of the industry and a 17.5% rise of the S&P 500.
The renowned global provider of sequencing systems has a market capitalization of $2.06 billion. The company projects 14.5% growth for 2023 and expects to maintain a strong performance. PacBio’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and broke even once, the average surprise being 9.5%.
Image Source: Zacks Investment Research
Let’s delve deeper.
Strategic Deals: We are optimistic about PacBio’s robust growth opportunities via its inking of a slew of strategic deals over the past few months. In August, the company and GeneDx announced a research collaboration with the University of Washington to study the capabilities of HiFi long-read whole genome sequencing to increase diagnostic rates in pediatric patients with genetic conditions.
Also, in August, PacBio entered into an agreement to acquire Apton Biosystems, Inc.
Product Development Activities: We are optimistic about PacBio's solid potential in the RNA-sequencing market, which has been fortifying the company’s footprint worldwide. In August, PacBio announced the commencement of customer shipments of Onso short-read sequencing instruments.
In April, PacBio announced the availability of its new high-throughput Nanobind DNA Extraction kits, another key product from its Circulomics acquisition.
Strong Q2 Results: PacBio saw a robust increase in its overall top line, including strong Product and Instrument revenues, in the second quarter of 2023. Solid geographical performances were also recorded. Continued strong prospects in the Revio and Onso systems, with customers placing orders for these, were also seen.
Downsides
Macroeconomic Concerns: Macroeconomic dynamics, including rising inflation and global supply-chain constraints, have adversely impacted PacBio’s customers and lengthened customer sales cycles. These factors could impact its revenues and results of operations throughout 2023.
Stiff Competition: PacBio operates in a highly competitive market where its competitors offer nucleic acid sequencing equipment or consumables. Many of these companies currently have greater resources and may be able to respond more quickly and effectively than PacBio to new or changing opportunities, technologies, standards or customer requirements.
Estimate Trend
PacBio has been witnessing a positive estimate revision trend for 2023. Over the past 90 days, the Zacks Consensus Estimate for its adjusted loss per share has narrowed from $1.29 to $1.18.
The Zacks Consensus Estimate for the company’s third-quarter 2023 revenues is pegged at $48.1 million, suggesting a 48.9% uptick from the year-ago quarter’s reported number.
Other Key Picks
A few other top-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , McKesson Corporation (MCK - Free Report) and Integer Holdings Corporation (ITGR - Free Report) .
DaVita, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 12.7%. DVA’s earnings surpassed estimates in three of the trailing four quarters and missed once, with an average surprise of 21.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DaVita has gained 4.7% against the industry’s 5.2% decline over the past year.
McKesson, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 10.7%. MCK’s earnings surpassed estimates in three of the trailing four quarters and missed once, with an average of 8.1%.
McKesson has gained 28.6% compared with the industry’s 50.9% rise over the past year.
Integer Holdings, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.1%. ITGR’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 8.4%.
Integer Holdings has gained 52.6% compared with the industry’s 0.2% rise over the past year.